Clinical Trial Search

Primary: Cocaine Use as Assessed by Proportion of Visits (Excluding Excused Absences) With Cocaine-negative Urine Drug Screen — 0.31; 0.24 proportion of visits

Primary: Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12 — 23.8; 38.3 percentage of participants — p=0.018

Primary: Number of Participants With an Emergency Room Visit or Hospitalization, or Death by Day 28 — 21; 16 Participants

Primary: Number of Patients Who Achieve CR or PR by Day 28 of Treatment — 62 Participants

Primary: ADCS-Clinical Global Impression of Change in Agitation (ADCS-CGIC-A) — 3.434; 3.442 score on a scale — p=0.9904

Primary: Change From Baseline in Height Adjusted Total Kidney Volume (htTKV) at Month 12 — 0.0236; 0.0288 milliliters per meter — p=0.5265

Primary: Phase Ib: Patients With Event(s) of Dose-limiting Toxicity — 0; 0 Participants

Primary: Number of Participants With Grade 2 or Higher Adverse Events (AEs) — 36; 36; 88; 87 Participants — p=0.92

Primary: Craving to Drink — 31.1; 33.2 score on a scale — p=.065

Primary: Number of Subjects With Treatment Emergent Adverse Events (TEAEs) — 1; 1; 0; 3 Participants

Primary: Number of Participants With Adverse Events and Serious Adverse Events — 2; 183; 4; 317 Participants

Primary: Number of Participants With Adverse Events (AEs) - Parts 1, 2 and 5 — 4; 16; 15; 284 Participants

Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 2; 5; 3; 0 Participants

Primary: Relative Percent Change in Ki67 Scores From Baseline to Week 2 — 25; 33 percent change — p=0.0433

Primary: Mean Change From Baseline (End of Phase A) in the CAARS-O:SV ADHD Symptoms Total Score (18 Items) to End of Phase B — -9.02; -9.71 score on a scale — p=0.5845